Clinically, the FB-7 neoadjuvant trial comparing neratinib, trastuzumab, or the combination, with chemotherapy, in patients with locally advanced HER2+ breast cancer, showed a numerically greater pCR rate with neratinib+trastuzumab compared to single agents28,29. Here, ERBB2 is linked to breast carcinoma.